Rosetta Receives NY State Clearance for Second-Gen Test for Cancer of Unknown Primary | GenomeWeb

Rosetta Genomics said this week that the New York State Department of Health has approved the company's miRview Mets 2 microRNA diagnostic, which is used to detect the source of cancers of unknown primary origin.

New York is the only state that requires an independent regulatory review for laboratory-developed tests, Rosetta noted.

With the approval, Rosetta said it can now market the test in all 50 US states.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.